Addressing Treatment Options for Multiple Myeloma


Provided by the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing.


Supported by educational grants from
Novartis Oncology and Takeda Oncology.

Overview

Multiple Myeloma (MM) is a malignant B-cell lymphoproliferative disorder that is the second most common hematologic malignancy, accounting for approximately 10% of hematologic cancers. Despite significant advances in MM care over the last several decades, nearly all patients relapse after first-line therapy. Identification of relapsed patients who require additional treatment and selection of an appropriate management strategy are critical decisions in long-term care of patients with MM. Choosing the wrong regimen can potentially preclude or compromise future treatment options, resulting in less-than-optimal long-term outcomes. Observation and close monitoring is an appropriate strategy for some patients with biochemical evidence of relapse, while patients with certain high-risk cytogenetic features or clinical evidence of disease progression require pharmacologic therapy. Clinicians must be able to develop individualized treatment plans that consider factors such as patient characteristics (eg, age, performance status), prior lines of therapy and response to therapy, prior adverse events, quality of life, and the patient’s treatment goals. Recent research has identified several new approaches that can improve outcomes for patients with relapsed MM, including new antitumor agents, multidrug combinations, and extended treatment regimens.

Target Audience

This activity is designed for oncology healthcare providers (oncologists, oncology nurses, and oncology physician assistants) who care for patients with MM.  No prerequisites required.

Learning Objectives

After participating in this activity, the participant will demonstrate the ability to:

  • IDENTIFY relapsing patients with MM who require immediate treatment, as well as those who are candidates for close observation and monitoring.
  • EVALUATE the most current data and clinical applications for approved and emerging treatment options in MM.
  • FORMULATE individualized treatment plans for MM using patient case scenarios.

The Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.

Additional information
Goal: 

To help clinicians to identify the right moment to begin therapy for patients with MM, to define treatment goals for each individual patient, and to select appropriate management strategies at different stages of the disease.

Accreditation Statement: 

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation Statement: 

The Johns Hopkins University School of Medicine designates this enduring material for a maximum of .5 AMA PRA Category I Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This .5 contact hours of educational activity is provided by the Institute for Johns Hopkins Nursing. Claim only those contact hours actually spent in the activity. Statements will be awarded for this educational activity until October 10, 2018.

The estimated time to complete this activity: 30 minutes.

Confidentiality Disclaimer for CME Activity Participant: 

I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am attending in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the “Privacy Regulations”). Protected health information is information about a person's health or treatment that identifies the person.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone:  410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”

Johns Hopkins University School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03)
(Updated 4/09 and 3/14)


Non-Endorsement of Products

The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity.

Disclaimer

The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.50 Nursing
Course opens: 
10/10/2016
Course expires: 
10/10/2018
Rating: 
0

Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME.

Policy on Faculty and Provider Disclosure
It is the policy of the Johns Hopkins University School of Medicine (and the Institute for Johns Hopkins Nursing) that the speaker and provider globally disclose conflicts of interest. The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the instructional materials.

The following relationships have been reported for this activity:

Chair and Planner
David S. Ettinger, MD
Alex Grass Professor in Oncology
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Nurse Planner
Rebecca Barshick, RN, MSN
Nurse Educator
The Institute for Johns Hopkins Nursing
Baltimore, Maryland

Participating Faculty
Cristina Gasparetto, MD
Associate Professor of Medicine
Division of Hematological Malignancies and Cellular Therapy
Department of Medicine
Duke Cancer Institute
Durham, North Carolina

Nurse Reviewer
Kathryn Mooney, MSN, ACNS-BC, BMTCN, OCN
Clinical Nurse Specialist, Blood and Marrow Transplant
Sidney Kimmel Comprehensive Cancer Center
The Institute for Johns Hopkins Nursing
Baltimore, Maryland

Participating Faculty Disclosures
Dr Gasparetto reports receiving grants/research support from Celgene and serving as a consultant/advisor for Celgene, Millennium Pharmaceuticals Inc, and Onyx Pharmaceuticals.

Planner Disclosures
Dr Ettinger reports serving as a principal investigator for Golden Biotechnology Corp; serving on the data monitoring committee for Ariad Pharmaceuticals Inc; and serving as a consultant for Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, EMD Serono Inc, and Genentech Inc, Helsinn Therapeutics, Inc.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

Off-Label Product Discussion
No faculty member has indicated that their presentation will include information on off-label products.

Non-Endorsement of Products
The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity.

Available Credit

  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.50 Nursing

Accreditation Period

Course opens: 
10/10/2016
Course expires: 
10/10/2018
Please login or register to take this course.

Required Hardware/software

Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.